Brawn Biotech P/E Ratio
Current P/E Ratio
31.4
High Valuation
Very High - High growth expectations or significantly overvalued
Brawn Biotech P/E ratio. Brawn Biotech (BRAWN) P/E ratio is 31.4 (High), EPS (TTM) ₹3.26, current price ₹24.50 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see Brawn Biotech share price today.
Current Valuation Metrics
P/E Ratio
31.4
Current Price
₹24.50
EPS (TTM)
₹3.26
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.45
Sector Median
32.41
Sector Rank
#11 of 199
Sector Percentile
5.5%
Earnings Breakdown (TTM)
TTM EPS
₹0.44
Mar 2023
₹0.47
Jun 2023
₹-0.08
BRAWN P/E Ratio — Valuation Signal & Historical Context
Brawn Biotech P/E 31.4 — signal: Overvalued. Also explore BRAWN share price charts to track price trends across different timeframes.
- Stock appears overvalued with PE of 31.4, suggesting caution for new investments
- Trading at discount to sector average PE of 56.45
BRAWN vs Healthcare Peers — P/E Ratio Comparison
Brawn Biotech P/E 31.4 vs Healthcare average 56.45, median 32.41 — range 2.04–740.29.
Sector Average
56.45
Sector Median
32.41
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.29 | ₹6,582 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| GKB Ophthalmics | GKB | 6.27 | ₹33 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |